Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and efficacy concerns in the U.S. after being selected for the FDA Commissioner’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results